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454a Tuesday, February 5, 2013activation of the voltage sensors in the fourth transmembrane segment (S4) is
transduced into pore opening via coupling of the S4-S5 linker to the C-terminal
S6 segment. In TRPA1, the gain-of-function mutation N855S located in the S4-
S5 region has been associated with familial episodic pain syndrome. In an at-
tempt to elucidate the role of the S4-S5 linker and its putative interaction(s)
with S6 or the first C-terminal helix in the voltage-dependent gating of
TRPA1, we used site-directed mutagenesis, whole-cell electrophysiology,
single-channel recording, and molecular dynamics simulations. The charge-
reversal mutations K868E and K969E resulted in a decrease in the rectification
index compared to wild-type TRPA1 channels, and a virtually voltage-
independent conductance-voltage (G-V) relationship. This effect was also ob-
served in the adjacent charge-neutralizing mutant H970A, but was less pro-
nounced in charge- reversal H970D. These results indicate that positively
charged residues in the S4-S5 linker and the helix adjacent to the C-terminal
S6 segment play a vital role in the voltage-dependent gating of TRPA1.
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Human skin is constantly exposed to solar ultraviolet radiation (UVR), the most
prevalent environmental carcinogen. Humans have the unique ability among
mammals to respond to UVR by increasing their skin pigmentation, a protective
process driven by melanin synthesis in epidermal melanocytes. However, the
mechanism used by melanocytes to detect and respond to UVR is not well un-
derstood. Here we report that transient receptor potential A1 (TRPA1) ion
channels expressed in human melanocytes are activated by UVR and mediate
early melanin synthesis. We show that in human epidermal melanocytes
(HEMs) physiological doses of UVR activate a retinal-dependent current me-
diated by TRPA1. The UVR photocurrent density was reduced by TRPA1 an-
tagonists and abolished in HEMs expressing TRPA1-targeted miRNA. The
TRPA1 photocurrent is UVA specific and requires G protein signaling, provid-
ing the first evidence for TRPA1 function in mammalian phototransduction. In
HEMs, TRPA1 activation contributes to UVR-induced calcium responses to
mediate downstream cellular effects. Remarkably, the UVR-induced and
retinal-dependent early increase in cellular melanin content was significantly
reduced in HEMs treated with TRPA1 antagonists and abolished in HEMs ex-
pressing TRPA1-targeted miRNA, suggesting that TRPA1 is required for early
melanin synthesis. Our results show that TRPA1 is essential for a novel extra-
ocular phototransduction pathway in human melanocytes that is activated by
physiological doses of UVR and results in early melanin synthesis.
2323-Pos Board B342
Characterization of Small Molecule TRPC3 and TRPC6 agonist and
Antagonists
Xiaoping Xu1, Irina Lozinskaya1, Melissa Costell1, Zuojun Lin1,
Jennifer A. Ball2, Roberta Bernard1, David J. Behm1, Joseph P. Marino1,
Christine G. Schnackenberg1.
1GlaxoSmithKline, King of Prussia, PA, USA, 2Bristol University, Bristol,
United Kingdom.
Canonical transient receptor potential channels (TRPC3/6) are mechano-
sensitive, receptor- and store-operated channels that mediate Ca2þ/Naþ influx
into cells. TRPC3/6 are implicated in the regulation of vascular tone, cell
growth, proliferation and pathological hypertrophy. Potent and selective small
molecule TRPC3/6 agonist and antagonist tools had been lacking to study the
functions of TRPC3/6. We report here potent, small molecule agonist
(GSK1702934A) and antagonists (GSK417651A and GSK2293017A) of
TRPC3/6. Whole-cell patch-clamp experiments demonstrated that
GSK1702934A activated TRPC3 and TRPC6 current in HEK293 cells trans-
duced with recombinant human TRPC3 or TRPC6 with an EC50 of ~
0.08 mM and 0.44 mM, respectively. GSK417651A inhibited both TRPC3
and TRPC6 current with IC50s of ~ 0.04 mM. A more potent TRPC3/6 antago-
nist GSK2293017A exhibited an IC50 of ~ 0.01 mM. GSK417651A was likely
acting on TRPC3/6 from the extracellular side, because dialyzing the cells with
10 mM GSK417651A in the pipette solution did not prevent the activation of
TRPC6. In the rat cardiomyocyte like cell line H9C2, GSK1702934A
(1 mM) activated TRPC6-like current which was completely blocked by
GSK417651A (1 mM). TRPC3/6 activator GSK1702934A (1 mM) transientlyincreased the perfusion pressure of isolated rat heart retrogradely perfused
via aortic cannulation. This effect was completely eliminated by pretreatment
with the TRPC3/6 blocker GSK2293017A (1 mM). IV bolus of GSK1702934A
(0.3 ~ 3 mg/kg) transiently increased blood pressure by 15 ~ 35 mmHg in con-
scious Sprague Dawley rats. This blood pressure effect was dose-dependently
inhibited by pretreatment of GSK2293017A (2.5 ~ 250 mg/kg/min infusion for
30 min) with complete inhibition occurring at a free plasma concentration of
0.81 mM. Therefore, these small molecule agonist and antagonists could be use-
ful tools to help understand the characteristics and functions of TRPC3/6 in tis-
sues and animals.
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Subfamily of human expressed TRPC channels (TRPC3/6/7) are activated by
‘diacylglycerol’ (DAG), a phospholipase C (PLC) hydrolyzed product of phos-
phatidylinositol 4,5-bisphosphate [PI(4,5)P2] (Hofmann et al., 1999, Nature).
In contrary, we have recently reported that the depletion of PI(4,5)P2 by-
itself act as a potent negative regulator to all these channels even in the pres-
ence of DAG (Imai et al., 2012, J. of Physiol.). Stimulation upon the vasocon-
strictile receptors coupled with PLC theoretically causes inseparable bimodal
effect to these TRPC channels, i.e. activation and inhibition by DAG produc-
tion and coincident PI(4,5)P2 reduction or depletion which is corresponding
to the strength of PLC activities. Here, to elucidate such self-limiting regulatory
function coupled to PI(4,5)P2-DAG signal, we simultaneously measure
TRPC6/7 currents in the whole-cell configuration and PI(4,5)P2 dynamics by
FRET using PI(4,5)P2 binding PH-domain sensor proteins in the various
strength of muscarinic- or vasopressin-receptor stimulation. Our simultaneous
detection approach reveals good kinetics correlation between TRPC activation/
fast-inactivation and PI(4,5)P2 depletion. Furthermore, a simple self-limiting
regulation model wherein experimentally determined PI(4,5)P2 binding con-
stants incorporated aware an emergence of fast recovery of PI(4,5)P2 to pro-
duce slow inactivation (plateau phase) of TRPC currents. We find that such
model implicated PI(4,5)P2 enhancement can be reproduced after the fast
PI(4,5)P2 depletion under the robust agonist stimulation by the local FRET
measurement near the channels. Hence, these data indicates that self-limiting
regulation coupled to PI(4,5)P2-DAG signal is the pivotal mechanism to under-
stand the receptor-PLC mediated TRPC3/6/7 channels activity.
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Canonical transient receptor potential (TRPC) channels have six transmem-
brane (6-TM) domains and are Ca2þ-permeable and non-selective cation chan-
nels. It is generally speculated that TRPC channels are activated by stimulation
of Gq-PLC-coupled receptors and oxidation. Activator of G-protein signaling1
(AGS1 or RASD1), the ras-related protein, interacts with Gi/Go and activates
heterotrimeric G-protein signaling systems independent of G-protein-coupled
receptor (GPCR). It is previously reported that AGS1 is related to GIRK chan-
nel and Ca2þ channel. However it is unknown whether AGS1 is associated with
TRPC channels. We assumed that AGS1 might regulate TRPC4 channel, since
AGS1 interacts with Gi/Go and TRPC4 is activated by Gi/o subunits. Here, we
measured whole cell current of TRPC4/5 after the co-expression of TRPC4 or
TRPC5 with constitutively active form of small GTPases in HEK293 cells.
AGS1 (CA) mutant (Q to L) activated TRPC4 (38.8 5 7.2 pA/pF) without
GTPgS and independently of GPCR. Pertussis toxin (PTX), Gai specific inhib-
itor, blocked RASD1-activated TRPC4 current (3.451.6 pA/pF). When co-
expressed with dominant negative Gai protein subtype, TRPC4 activation by
RASD1 was completely inhibited. With previous report that TRPC4 are acti-
vated primarily by selective Gai subunits rather than Gaq, these results suggest
that AGS1 activates TRPC4 channel through modulating Gai subunits and
AGS1 is a new activator for TRPC4 channel.
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The Transient Receptor Potential Canonical 4 (TRPC4) channel is a Ca2þ-per-
meable, non-selective cation channel in mammalian cells and mediates
